JP2023510158A5 - - Google Patents
Info
- Publication number
- JP2023510158A5 JP2023510158A5 JP2022539136A JP2022539136A JP2023510158A5 JP 2023510158 A5 JP2023510158 A5 JP 2023510158A5 JP 2022539136 A JP2022539136 A JP 2022539136A JP 2022539136 A JP2022539136 A JP 2022539136A JP 2023510158 A5 JP2023510158 A5 JP 2023510158A5
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- approximately
- solid dosage
- capsule
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962954153P | 2019-12-27 | 2019-12-27 | |
| US62/954,153 | 2019-12-27 | ||
| PCT/US2020/066828 WO2021133904A1 (en) | 2019-12-27 | 2020-12-23 | Solid dosage forms containing bacteria and microbial extracellular vesicles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510158A JP2023510158A (ja) | 2023-03-13 |
| JP2023510158A5 true JP2023510158A5 (https=) | 2024-01-05 |
Family
ID=74626080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539136A Pending JP2023510158A (ja) | 2019-12-27 | 2020-12-23 | 細菌及び微生物細胞外小胞を含有する固形剤形 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230355689A1 (https=) |
| EP (1) | EP4081195A1 (https=) |
| JP (1) | JP2023510158A (https=) |
| KR (1) | KR20220128362A (https=) |
| CN (1) | CN114945357A (https=) |
| AR (1) | AR122353A1 (https=) |
| AU (1) | AU2020413225A1 (https=) |
| BR (1) | BR112022012514A2 (https=) |
| CA (1) | CA3165418A1 (https=) |
| CO (1) | CO2022010242A2 (https=) |
| MX (1) | MX2022007943A (https=) |
| TW (1) | TW202135783A (https=) |
| WO (1) | WO2021133904A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021252861A1 (en) * | 2020-06-11 | 2021-12-16 | Evelo Biosciences, Inc. | Compositions and methods for treating diseases and disorders using megasphaera sp |
| EP4185307A1 (en) * | 2020-07-21 | 2023-05-31 | Evelo Biosciences, Inc. | Veillonella parvula strain as an oral therapy for neuroinflammatory diseases |
| KR20240093504A (ko) * | 2021-09-24 | 2024-06-24 | 에벨로 바이오사이언시즈, 인크. | 박테리아 및 미생물 세포외 소포를 함유하는 고체 투여 형태 |
| EP4429684A1 (en) * | 2021-12-16 | 2024-09-18 | Enterobiome Inc. | Pharmaceutical composition for preventing or treating cancer or inflammatory disease |
| CN115252651B (zh) * | 2022-06-08 | 2024-06-07 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物 |
| JP2025530743A (ja) * | 2022-08-29 | 2025-09-17 | イーライ リリー アンド カンパニー | 経口投与のための組成物 |
| CN116509900B (zh) * | 2022-12-01 | 2023-11-10 | 佛山科学技术学院 | 益生菌或其细胞外囊泡在制备防治胃溃疡产品中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775536A (en) | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| US5292522A (en) | 1989-06-20 | 1994-03-08 | Rohm Gmbh | Aqueous film coating agent for solid medicaments |
| US5047258A (en) | 1989-07-14 | 1991-09-10 | Sterling Drug Inc. | Aqueous spray-coating process |
| US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| DE19631084A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
| US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| DE19937361A1 (de) * | 1999-08-12 | 2001-02-22 | Merck Patent Gmbh | Orale Darreichungsform |
| US20040028737A1 (en) | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
| DE10260919A1 (de) | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug |
| EP1677770A2 (en) | 2003-10-31 | 2006-07-12 | Dexcel Ltd. | Stable lansoprazole formulation |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| CN101209247B (zh) * | 2006-12-27 | 2011-12-14 | 天津中新药业集团股份有限公司 | 一种结肠靶向制剂的制备方法 |
| CN101757042A (zh) * | 2009-05-25 | 2010-06-30 | 北京诚创康韵医药科技有限公司 | 一种益生菌微丸制剂及其制备 |
| SG11201503966PA (en) * | 2012-11-23 | 2015-06-29 | Seres Health Inc | Synergistic bacterial compositions and methods of production and use thereof |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| MX357575B (es) | 2013-03-01 | 2018-07-16 | Bpsi Holdings Llc | Recubrimientos de pelicula de liberacion retardada que contienen silicato de calcio y sustratos recubiertos con los mismos. |
| AU2014239883B2 (en) * | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| WO2019152667A1 (en) * | 2018-01-31 | 2019-08-08 | Evelo Biosciences, Inc. | Compositions and methods for treating immune disorders using lachnospiraceae bacteria |
-
2020
- 2020-12-23 AR ARP200103650A patent/AR122353A1/es not_active Application Discontinuation
- 2020-12-23 MX MX2022007943A patent/MX2022007943A/es unknown
- 2020-12-23 BR BR112022012514A patent/BR112022012514A2/pt not_active Application Discontinuation
- 2020-12-23 JP JP2022539136A patent/JP2023510158A/ja active Pending
- 2020-12-23 KR KR1020227025604A patent/KR20220128362A/ko active Pending
- 2020-12-23 AU AU2020413225A patent/AU2020413225A1/en active Pending
- 2020-12-23 CN CN202080090020.6A patent/CN114945357A/zh active Pending
- 2020-12-23 CA CA3165418A patent/CA3165418A1/en active Pending
- 2020-12-23 US US17/789,427 patent/US20230355689A1/en active Pending
- 2020-12-23 WO PCT/US2020/066828 patent/WO2021133904A1/en not_active Ceased
- 2020-12-23 EP EP20853582.3A patent/EP4081195A1/en not_active Withdrawn
- 2020-12-25 TW TW109146331A patent/TW202135783A/zh unknown
-
2022
- 2022-07-19 CO CONC2022/0010242A patent/CO2022010242A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510158A5 (https=) | ||
| JP2022537684A5 (https=) | ||
| JP2022538765A5 (https=) | ||
| AU2018230495B2 (en) | Compositions and methods for promoting a healthy microbial flora in a mammal | |
| CN1039194C (zh) | 二甲胺四环素脉冲式一日一次释放系统 | |
| RU2114619C1 (ru) | Перорально вводимая лекарственная форма | |
| JP6099638B2 (ja) | エタノールの影響に耐性のある胃液抵抗性の医薬又は栄養補助組成物 | |
| CN1316901A (zh) | 富马酸衍生物在移植药物中的应用 | |
| CN1050320A (zh) | 二甲胺四环素的一天一次脉冲的传递系统 | |
| CN101815509A (zh) | 营养剂量单位 | |
| KR101686176B1 (ko) | 내산성 및 안정성이 향상된 프로바이오틱스 코팅 고체 조성물의 제조 방법 | |
| CN102341100A (zh) | 用于口服递送的活细胞制剂 | |
| RU2738114C2 (ru) | Пероральные фармацевтические композиции никотинамида | |
| CN109568284A (zh) | 一种替诺福韦艾拉酚胺肠溶片及其制备方法 | |
| RU2008120672A (ru) | Композиции для перорального введения, содержащие тайгециклин | |
| CN102058544B (zh) | 非诺贝特酸胆碱盐肠溶缓释微丸的制备方法 | |
| Vejdani et al. | Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: a placebo controlled study | |
| KR102777246B1 (ko) | 결장 약물 운반 제형 | |
| JP2024516110A5 (https=) | ||
| CN101933919A (zh) | 棕矢车菊素的用途 | |
| TW202038915A (zh) | 結腸藥物遞送配方 | |
| DE102017104482A1 (de) | Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug | |
| AU2016280148A1 (en) | Extended release Capecitabine capsules | |
| TW201022215A (en) | Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same | |
| CN101683340A (zh) | 一种复方盐酸二甲双胍罗格列酮的缓释制剂及其制备方法 |